Table 7.
The PCM1 variant is not associated with overall survival in ovarian cancer
| Type 3 tests
| |||||||
|---|---|---|---|---|---|---|---|
| Effect | DF | Wald χ2 | Pr>χ2 | ||||
| Age | 1 | 5.0475 | 0.0247 | ||||
| Stage_yale__X_means_ | 3 | 8.7872 | 0.0323 | ||||
| PCM1 variant | 1 | 3.1046 | 0.0781 | ||||
| Histo | 1 | 0.0836 | 0.7725 | ||||
|
| |||||||
|
Analysis of maximum likelihood estimates
| |||||||
| Parameter | DF | Parameter estimate | Standard error | χ2 | Pr>χ2 | Hazard ratio | Label |
|
| |||||||
| Age | 1 | 0.02907 | 0.01294 | 5.0475 | 0.0247 | 1.029 | Age |
| Stage_yale__X_means_1 | 1 | 0.11009 | 0.74131 | 0.0221 | 0.8819 | 1.116 | Stage yale (X means neoadjuvant) 1 |
| Stage_yale__X_means_2 | 1 | −2.02514 | 0.75154 | 7.2611 | 0.0070 | 0.132 | Stage yale (X means neoadjuvant) 2 |
| Stage_yale__X_means_3 | 1 | −0.42677 | 0.25765 | 2.7436 | 0.0976 | 0.653 | Stage yale (X means neoadjuvant) 3 |
| PCM1 ATTT insertion | 1 | 0.52038 | 0.29534 | 3.1046 | 0.0781 | 1.683 | rs17931372 ATTT insertion |
| Histo other | 1 | −0.16139 | 0.55834 | 0.0836 | 0.7725 | 0.851 | Histo Other |
Multivariate analysis adjusted for age, stage and histology.